# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears® Supplement for Dry Eyes, Blink® Triple...
Morgan Stanley analyst Patrick Wood upgrades Bausch & Lomb (NYSE:BLCO) from Equal-Weight to Overweight and raises the pr...
HC Wainwright & Co. analyst Yi Chen reiterates Bausch & Lomb (NYSE:BLCO) with a Buy and maintains $20 price target.
Needham analyst David Saxon reiterates Bausch & Lomb (NYSE:BLCO) with a Hold.
Bausch & Lomb (NYSE:BLCO) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05...
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc...